Amneal Pharmaceuticals (AMRX) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 434.2% versus a gain of 89.7%. Over five years, AMRX leads with a +248.4% price change compared with -7.4% for PRAX. Praxis Precision Medicines is the larger company by market cap ($7.76 billion vs $6.84 billion), about 1.1 times the size, while Amneal Pharmaceuticals is growing revenue faster (+8.0% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | PRAX |
|---|---|---|
| Share price | $19.65 | $278.02 |
| Market cap | $6.84B | $7.76B |
| 1-day change | -3.18% | -0.76% |
| YTD return | +55.95% | -5.67% |
| 1-year return | +89.67% | +434.24% |
| 5-year return | +248.40% | -7.37% |
| P/E ratio (TTM) | 40.10 | — |
| Forward P/E | 16.48 | — |
| EPS (TTM) | $0.49 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $0 |
| Revenue growth (YoY) | +8.05% | -100.00% |
| Net income (latest FY) | $72.06M | $-303.27M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | — |
| Net margin | 2.39% | — |
| 52-week high | $21.18 | $392.70 |
| 52-week low | $9.56 | $50.56 |
| Distance from 52-week high | -7.20% | -29.20% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.57% | +131.79% |
| Average volume | 2.22M | 404.98K |
| Shares outstanding | 348.30M | 27.92M |
| Employees | 8,700 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed AMRX by 344.6 percentage points over the past year.
- Amneal Pharmaceuticals grew revenue faster in its latest fiscal year (+8.05% vs -100.00%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
AMRX vs PRAX FAQ
Which is bigger, Amneal Pharmaceuticals or Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.76B compared with $6.84B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or PRAX?
PRAX returned +434.24% over the past 12 months, compared with +89.67% for AMRX (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.